NEXTURNBIOSCIENCE Co., LTD
089140 | KO
Overview
Corporate Details
- ISIN(s):
- KR7089140008
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 기흥단지로121번길 35 (고매동), 용인시
- Website:
- http://www.nexturn.co.kr
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-26 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 107.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 69.6 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-07 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.1 KB | ||
| 2025-08-07 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 86.1 KB | ||
| 2025-07-30 00:00 |
Share Issue/Capital Change
전환청구권행사
|
Korean | 9.1 KB | ||
| 2025-07-28 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.7 KB | ||
| 2025-07-16 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(자기전환사채매도결정)
|
Korean | 62.7 KB | ||
| 2025-07-16 00:00 |
M&A Activity
주요사항보고서(회사합병결정)
|
Korean | 95.5 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 6.0 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.7 KB | ||
| 2025-07-03 00:00 |
M&A Activity
합병등종료보고서(합병)
|
Korean | 21.8 KB |
Automate Your Workflow. Get a real-time feed of all NEXTURNBIOSCIENCE Co., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for NEXTURNBIOSCIENCE Co., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NEXTURNBIOSCIENCE Co., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
Spain
IKM
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
Sweden
2CUREX
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
Sweden
ABERA
South Korea
203400
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
South Korea
298380
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
United States of America
ABP
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
United States of America
ABSI
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland
ACHI
Switzerland
ACHI
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
Sweden
ACTI
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
United States of America
ADAG